1. In Vivo

In Vivo's Deals Of The Month, August 2016

 
• By Nancy Dvorin

In Vivo's editors pick August's most significant deals, including a neuromodulation joint venture and big money for a newish IO drug developer. (Article free with registration.)

GlaxoSmithKline PLC and Verily Life Sciences will invest up to £540 million ($702 million) over the next seven years in Galvani Bioelectronics, a new joint venture dedicated to breaching the next frontier in neuromodulation technologies. (Also see "New GSK-Verily JV Aims For Smart, 'Grain Of Rice' Neuromod Tech" - Medtech Insight, 2 August, 2016.) [See Deal] GSK, which will hold a 55% stake in the company, will contribute its drug development expertise, understanding of disease biology and know-how in getting clinical proof and evidence. Verily brings to the table its expertise in miniaturization technology, device development, as well as data analytics, machine learning and software development. Galvani's mission is to explore multiple areas within inflammatory, metabolic and endocrine disorders, including type 2 diabetes, where Verily already has existing product development collaborations with DexCom Inc. and Sanofi.

Ten-year old Tioma Therapeutics Inc., which is developing immunotherapies for solid and blood cancers, raised $86 million in a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

More from In Vivo

Dealmaking Quarterly Statistics, Q2 2025

 
• By Maureen Riordan and Deanna Kamienski

During Q2, biopharma merger and acquisition deal value reached $24.6bn and drew in $60.7bn in potential deal value from alliances. Device company M&A values reached $223m, while in vitro diagnostics and research tools players’ M&A activity totaled $802m.

PBMs Tighten The Reins: Value Becomes The New Access Gatekeeper

 
• By Andrew Cox

Facing rising costs and tighter regulations, PBMs and insurers are accelerating the shift to value-based drug coverage, demanding stronger proof of therapeutic and economic benefit from pharma.

Akelos’ Peripheral HCN1 Blocker Looks To End Opioid Dependence In Neuropathic Pain

 
• By Jo Shorthouse

Akelos is developing a first-in-class, non-addictive HCN1 inhibitor for peripheral neuropathic pain, based on anesthesiology research from Weill Cornell. The compound is designed to avoid the brain and heart, and has shown strong preclinical efficacy and safety with NIH backed development underway.